Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e43-5. doi: 10.1097/QAI.0000000000000935.

Authors

Eve Todesco¹, Laure Surgers, Anne-Geneviève Marcelin, Vincent Calvez, Jean-Luc Meynard, Laurence Morand-Joubert

Affiliation

¹ *Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), INSERM, Sorbonne Universités, UPMC Univ Paris 06, Paris, France †Department of Virology, Hôpital Saint-Antoine, APHP, Paris, France ‡Department of Virology, Hôpital Pitié-Salpêtrière, APHP, Paris, France §Department of Infectious Diseases, Hôpital Saint-Antoine, APHP, Paris, France Sorbonne University, UPMC Univ Paris 06 CR7, INSERM U1135, CIMI, Team E13, Paris, France.

PMID: 26818741
DOI: 10.1097/QAI.0000000000000935

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents / therapeutic use*
Drug Resistance, Viral / genetics*
Emtricitabine / therapeutic use*
Genotyping Techniques
HIV Infections / drug therapy*
HIV-1 / drug effects
HIV-1 / genetics
HIV-1 / isolation & purification
High-Throughput Nucleotide Sequencing
Humans
RNA-Directed DNA Polymerase / genetics
RNA-Directed DNA Polymerase / metabolism
Rilpivirine / therapeutic use*
Tenofovir / therapeutic use*
Viral Load

Substances

Anti-HIV Agents
Tenofovir
RNA-Directed DNA Polymerase
Rilpivirine
Emtricitabine